Expert Perspectives on Advances in the Management of C. difficile : Episode 13

C. Difficile Treatment: Bezlotoxumab

January 8, 2021

Video

The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.

EP: 1.C. Difficile Risk Factors and Manifestation

EP: 2.Strains of C. Difficile

EP: 3.Managing Community-Onset C. Difficile

EP: 4.Recurrent C. Difficile

EP: 5.C. Difficile: A Differential Diagnosis

EP: 6.Testing for C. Difficile Infections

EP: 7.Screening for C. Difficile

EP: 8.C. Difficile: Clinical Practice Guidelines and Treatment Options

EP: 9.C. Difficile: Updates to Clinical Practice Guidelines

EP: 10.Selecting Therapy to Treat C. Difficile

EP: 11.C. Difficile Treatment: Fidaxomicin

EP: 12.Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections

Now Viewing

EP: 13.C. Difficile Treatment: Bezlotoxumab

EP: 14.Preventing/Treating C. Difficile: Unmet Needs

EP: 15.Fecal Microbiota Transplantation for C. Difficile Infections

EP: 16.Emerging Treatment Options for C. Difficile Infections

EP: 17.C. Difficile: Barriers Treating With FMT

EP: 18.Making Strides in the Management of C. Difficile

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!